
The healthcare community faces an increasing clinical challenge in preventing and controlling the growing emergence of resistant organisms. Tigecycline (Tygacil, Wyeth) is one of a slim list of new antibiotics in development that shows substantial promise as a broad-spectrum agent with activity against many resistant gram-positive bacteria and, to a lesser extent, gram-negative bacteria.